Literature DB >> 2447223

Antiviral activity of monoclonal antibodies specific for the internal proteins N and NS of rabies virus.

M Lafon1, M Lafage.   

Abstract

Monoclonal antibodies (MAbs) specific for the rabies virus nucleoprotein (N protein) and non-structural (NS) protein of the nucleocapsid were introduced into adherent cells (fibroblasts and neuroblastoma) by the scrape-loading technique. After the cells had reattached to the substrate, they were infected with rabies virus. Inhibition of infection was monitored by measuring the intracytoplasmic viral nucleocapsid accumulation with an enzyme immunoassay using anti-N protein rabbit serum and by measuring the release of infectious virus with the plaquing system. Seventeen MAbs defining the three independent antigenic sites on the N protein were able to decrease nucleocapsid accumulation and the release of infectious virus. The MAbs describing the two antigenic sites on NS protein also had an antiviral effect on ERA virus. When an anti-N MAb (0.5 ng per cell) was introduced into CVS-infected cells, virus inhibition was complete if the anti-N MAb was introduced between 0 and 5 h post-infection and ineffective beyond 9 h post-infection. The inhibition was dose-dependent. The MAbs could block virus multiplication either by 'neutralizing' newly translated N and NS proteins or by impairing the initial transcription of the genome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447223     DOI: 10.1099/0022-1317-68-12-3113

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

Authors:  D L Lodmell; J W Sumner; J J Esposito; W J Bellini; L C Ewalt
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Polygenic control of antibody production and correlation with vaccine induced resistance to rabies virus in high and low antibody responder mice.

Authors:  M De Franco; S Massa; R C Vassão; M Siqueira; O A Sant'Anna
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Human immune response to rabies nucleocapsid and glycoprotein antigens.

Authors:  S Kasempimolporn; T Hemachudha; P Khawplod; S Manatsathit
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

5.  Electroporation of functional bacterial effectors into mammalian cells.

Authors:  Ryan L Sontag; Cosmin Mihai; Galya Orr; Alexei Savchenko; Tatiana Skarina; Hong Cui; John R Cort; Joshua N Adkins; Roslyn N Brown
Journal:  J Vis Exp       Date:  2015-01-19       Impact factor: 1.355

6.  Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection.

Authors:  Y Takita-Sonoda; H Fujii; K Mifune; Y Ito; M Hiraga; A Nishizono; K Mannen; N Minamoto
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  The neural cell adhesion molecule is a receptor for rabies virus.

Authors:  M I Thoulouze; M Lafage; M Schachner; U Hartmann; H Cremer; M Lafon
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro.

Authors:  D L Lodmell; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies.

Authors:  Pauline Ménager; Pascal Roux; Françoise Mégret; Jean-Pierre Bourgeois; Anne-Marie Le Sourd; Anne Danckaert; Mireille Lafage; Christophe Préhaud; Monique Lafon
Journal:  PLoS Pathog       Date:  2009-02-27       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.